out on Lancet oncology by Vivek subbiah and team
The ROAR trial: DABRAFENIB PLUS TRAMETINIB in patients with VRAF V600E mutation biliary tract cancer showing 51% Overall response rates

EMBRACA trial in Annals of oncology show no OS benefit with TALOZOPARIB vs chemo
in HER2 negative breast cancer and germline BRCA pathogenic variants

on Journal of GI oncology
Circulating tumor DNA and plasma MSI during PD-1 blockade by pashtoon Kasi

on JCO
FOLFOXIRI bevacizumab significantly improves survival in metastatic colorectal cancer compared with doublets bevacizumab
and provides advantage in PFS & ORR

Out in cancer treatment
Summary of efficacy data of APALUTAMIDE, DAROLUTAMIDE & ENZALUTAMIDE in non metastatic castrate resistant prostate cancer

Out on JCO
RUCAPARIB has antitumor activity in patients with metastatic castrate resistant prostate cancer and a deleterious BRCA alteration

ESR & ERS release a joint statement on lung cancer screening in Europe, heavy emphasis on tobacco cessation, education and
promotion of active lifestyles

Teen and young adults who use e-cigaretes
are 5-7 times more likely to be diagnosed with covid19 than non vapers

Preview to ESMO20 virtual

MERCK releases news of KEYNOTE-590
pembrolizumab in Combo With Chemo Significantly Improved OS and PFS Compared With Chemo in Locally Advanced or First-Line Metastatic Esophageal Cancer

Out on Lancet
Oral metronomic chemotherapy is non-inferior to intravenous cisplatin with respect to overall survival in head and neck cancer in the palliative setting

Correspondence on European Urology
Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti–PD-1 Immune Checkpoint Inhibitors
Sees that a higher microbial diversity is associated with better treatment outcomes.

Out in Nature
Why do younger female patients not respond as well to immunotherapy?
Accumulation of cancer causing genetic mutations could be a reason

Out on Nature cancer and cancer discovery
liquid biopsy could help better ID patients benefiting from immunotherapy in advanced cancer.

Reminder that we have less than 30 days until ESMO 20 and registration is free for ESMO members

A huge hug to our oncoalert colleague Mark Lewis who just got amazing news!!